Literature DB >> 9144007

Aeromonas bacteremia in patients with hematologic diseases.

H Funada1, T Matsuda.   

Abstract

Over a 23-year period, 17 patients with hematologic diseases developed Aeromonas bacteremia while in our hematology ward. Male predominance (14 patients, 82%) was seen, with a predilection for the elderly. Hematologic malignancies, especially acute leukemia, accounted for 15 (88%) of all patients. Cancer chemotherapy and neutropenia (15 patients each) were the most common preceding host conditions. Aeromonas bacteremia generally occurred in the second half of the year (July-December), with no exposure to water or fish. Seven recent isolates comprised Aeromonas sobria (five isolates) and Aeromonas hydrophila (two isolates). Twelve patients (71%) showed a clinical picture ranging from mild gastroenteritis to severe enterocolitis. Anorectal and hepatobiliary infections were also noted in a few patients. The overall mortality rate was 35%. Ten (77%) of the 13 patients who were treated with aminoglycoside plus cephalosporin or carbapenem survived in association with marrow recovery.

Entities:  

Mesh:

Year:  1997        PMID: 9144007     DOI: 10.2169/internalmedicine.36.171

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  8 in total

1.  In vitro and in vivo combinations of cefotaxime and minocycline against Aeromonas hydrophila.

Authors:  W C Ko; H C Lee; Y C Chuang; S H Ten; C Y Su; J J Wu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Complement resistance is essential for colonization of the digestive tract of Hirudo medicinalis by Aeromonas strains.

Authors:  Thomas R Braschler; Susana Merino; Juan M Tomás; Joerg Graf
Journal:  Appl Environ Microbiol       Date:  2003-07       Impact factor: 4.792

3.  Pathogenic Aeromonas hydrophila serogroup O:14 and O:81 strains with an S layer.

Authors:  Consuelo Esteve; Elena Alcaide; Rocío Canals; Susana Merino; Dolores Blasco; Maria José Figueras; Juan M Tomás
Journal:  Appl Environ Microbiol       Date:  2004-10       Impact factor: 4.792

4.  In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.

Authors:  Wen-Chien Ko; Shyh-Ren Chiang; Hsin-Chun Lee; Hung-Jen Tang; Yin-Yi Wang; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

5.  Clinical features and outcome of Aeromonas sobria bacteremia in pediatric and adult patients with hematologic malignancies: A single-center retrospective study in Peru.

Authors:  Bryan Valcarcel; Gabriel De-la-Cruz-Ku; Luis Malpica; Daniel Enriquez-Vera
Journal:  PLoS One       Date:  2021-08-11       Impact factor: 3.240

6.  Different clinical characteristics among Aeromonas hydrophila, Aeromonas veronii biovar sobria and Aeromonas caviae monomicrobial bacteremia.

Authors:  Han-Chuan Chuang; Yu-Huai Ho; Chorng-Jang Lay; Lih-Shinn Wang; Yeong-Shu Tsai; Chen-Chi Tsai
Journal:  J Korean Med Sci       Date:  2011-10-27       Impact factor: 2.153

7.  A case of severe sepsis presenting marked decrease of neutrophils and interesting findings on dynamic CT.

Authors:  Isamu Makino; Hidehiro Tajima; Hirohisa Kitagawa; Hisatoshi Nakagawara; Tomoharu Miyashita; Shinichi Nakanuma; Hironori Hayashi; Hiroyuki Takamura; Sachio Fushida; Tetsuo Ohta
Journal:  Am J Case Rep       Date:  2015-05-28

8.  Clinical and Therapeutic Implications of Aeromonas Bacteremia: 14 Years Nation-Wide Experiences in Korea.

Authors:  Ji Young Rhee; Dong Sik Jung; Kyong Ran Peck
Journal:  Infect Chemother       Date:  2016-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.